WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced a strategic restructuring aimed at reducing costs and broadening the reach of YCANTH®, its treatment for molluscum contagiosum.
This move will cut sales territories from 80 to approximately 35, concentrating on areas with high molluscum prevalence and robust insurance support.
By focusing sales efforts on pediatricians in addition to dermatology offices, the company expects to decrease operating expenses by around fifty percent.
This initiative includes reducing headcount in support functions and incurring a one-time restructuring charge of about $1 million, all while sustaining support for YCANTH® as a standard of care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.